HC Wainwright Issues Positive Estimate for Annexon Earnings

Annexon, Inc. (NASDAQ:ANNX) – Analysts at HC Wainwright boosted their Q1 2026 earnings estimates for shares of Annexon in a research report issued on Thursday, April 2nd. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of ($0.31) for the quarter, up from their prior estimate of ($0.36). The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon’s Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.22) EPS, FY2027 earnings at ($0.94) EPS, FY2028 earnings at ($0.55) EPS and FY2029 earnings at ($0.05) EPS.

ANNX has been the topic of a number of other research reports. Chardan Capital reissued a “buy” rating and issued a $16.00 price target on shares of Annexon in a research note on Friday, March 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, January 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a report on Wednesday, January 14th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Annexon presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Annexon Stock Performance

Annexon stock traded up $0.05 during trading on Tuesday, reaching $5.85. The company had a trading volume of 909,555 shares, compared to its average volume of 2,675,806. The firm’s 50-day simple moving average is $5.51 and its 200 day simple moving average is $4.64. Annexon has a 1-year low of $1.28 and a 1-year high of $7.18. The firm has a market capitalization of $937.95 million, a PE ratio of -4.30 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Annexon by 65.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after acquiring an additional 2,785 shares during the period. Landscape Capital Management L.L.C. purchased a new position in shares of Annexon during the 4th quarter worth $50,000. CIBC Bancorp USA Inc. purchased a new position in shares of Annexon during the 3rd quarter worth $31,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Annexon during the 4th quarter worth $52,000. Finally, Mount Vernon Associates Inc. MD purchased a new position in shares of Annexon during the 4th quarter worth $53,000.

Insider Buying and Selling

In other Annexon news, EVP Michael Overdorf sold 6,225 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.10, for a total value of $31,747.50. Following the transaction, the executive vice president owned 124,464 shares in the company, valued at approximately $634,766.40. This trade represents a 4.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Dean Richard Artis sold 5,290 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total value of $26,979.00. Following the completion of the transaction, the executive vice president owned 123,487 shares in the company, valued at $629,783.70. The trade was a 4.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 32,513 shares of company stock worth $165,973 in the last ninety days. Company insiders own 11.87% of the company’s stock.

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.